Syndax Pharmaceuticals' IPO

Syndax Pharmaceuticals raised a round of funding on March 03, 2016. Investors include Public.

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immuno…

Articles about Syndax Pharmaceuticals' IPO: